U.S. Army awards veterinary college researcher $1 million grant to develop vaccine

Blacksburg, Va. -- A bacteriologist in the Virginia-Maryland Regional College of Veterinary Medicine has been awarded a $1.06 million grant from the U.S. Army to develop a vaccine for tularemia.

Thomas J. Inzana, the Tyler J. and Francis F. Young Professor of Bacteriology at Virginia Tech and his research team in the college's Center for Molecular Medicine and Infectious Diseases have begun a four-year program to develop a vaccine and diagnostic test for tularemia, which is commonly known as "rabbit fever." The etiologic agent of tularemia is Francisella tularensis, which the Centers For Disease Control (CDC) classifies as a Category A bioterrorism agent.

Tularemia is an infection characterized by ulcers, swollen glands, fever, and flu-like symptoms. The organism can spread through the blood and lymphatic systems to infect the respiratory tract, where it can cause more serious health problems. Pneumonic tularemia may have about a 30 percent mortality rate, according to Inzana.

While not uncommon in wildlife throughout the United States, Inzana says, it is a relatively rare disease in people. Only about 100-200 cases of tularemia in humans are reported every year, Inzana says. The bacteria are transmitted to humans and animals by ticks and biting flies, or can be ingested by wildlife from drinking water. Humans are also infected through minor cuts or abrasions on the hands by handling infected animals.

The military is concerned about F. tularensis because of its heartiness and its virulence. Whereas about 10,000 Bacillus anthracis (anthrax) spores are required to cause disease, only about 10 F. tularensis cells are required to cause disease, according to Inzana. The organism could conceivably be aerosolized and used as a bioterrorism agent at home or abroad; hence, the military interest. A World Health Organization Committee estimated that aerosol dispersal of 50 kilograms of virulent F. tularensis over a city of 5 million peop

Contact: Jeffrey S. Douglas
Virginia Tech

Page: 1 2 3

Related biology news :

1. Chemical engineering grad students will take notable national awards
2. NIH awards $18.2m to The Burnham Institute to develop Center on Proteolytic Pathways
3. NSF awards 22 new projects for plant genome research
4. The American Phytopathological Society announces 2004 awards
5. NSF announces six FIBR awards to tackle some of biologys most challenging questions
6. Two Virginia Tech energy-related inventions win R&D 100 awards
7. APS awards more than $140,000 to minority students of physiology
8. APS awards more than $36,000 to its 2004 undergraduate research fellows
9. 8 environmental stewards win $900,000 in biodiversity awards
10. UCSB professor and director receives two national awards
11. NSF awards $10 million in grants to ocean sites for long-term ecological research

Post Your Comments:

(Date:7/31/2020)... (PRWEB) , ... July 30, 2020 , ... ... prescription digital therapeutics product portfolio with a near term focus on Type 2 ... and pharma commercialization experience across multiple therapeutic areas and classes. As Chief Commercial ...
(Date:7/18/2020)... ... July 17, 2020 , ... Commercial launch readiness is ... ability to discover a COVID cure or vaccine, the global economic downturn will only ... pressure is not going away and capturing full value from every product launch is ...
(Date:7/4/2020)... ... July 03, 2020 , ... Aesthetics Biomedical (ABM), a leading ... for not only the products and treatments developed, but also the dedicated team ... All the brands built by ABM have received several honors already for 2020, ...
Breaking Biology News(10 mins):
(Date:7/18/2020)... MILWAUKEE (PRWEB) , ... July 16, 2020 , ... “We ... at Third Wave Bioactives. “It’s the only technology of its kind on the market ... flavor of onions with the protective capacity of traditional cultured ingredients, creating a natural ...
(Date:7/10/2020)... , ... July 08, 2020 , ... ... and products, announces a significant expansion of laboratory operations through its COVID-19 ... agencies implementing testing programs. , Bode-CARES provides a turnkey solution ...
(Date:7/10/2020)... ... 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology company ... Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. Dr. Nissenson will join ... Dr. Nissenson serves as an Emeritus Professor of Medicine at the David ...
(Date:7/1/2020)... N.C. (PRWEB) , ... June 29, 2020 , ... ... reported year to date growth of 40% in 2020, despite many obstacles created ... technology, MedShift aims to increase revenue for its partnered medical practices and medical ...
Breaking Biology Technology:
Cached News: